Literature DB >> 20434356

Neonatal diabetes mellitus: a model for personalized medicine.

Siri Atma W Greeley1, Susan E Tucker, Rochelle N Naylor, Graeme I Bell, Louis H Philipson.   

Abstract

Neonatal diabetes mellitus occurs in approximately 1 out of every 100,000 live births. It can be either permanent or transient, and recent studies indicate that is likely to have an underlying genetic cause, particularly when diagnosed before 6 months of age. Permanent neonatal diabetes is most commonly due to activating mutations in either of the genes encoding the two subunits of the ATP-sensitive potassium channel. In most of these patients, switching from insulin to oral sulfonylurea therapy leads to improved metabolic control, as well as possible amelioration of occasional associated neurodevelopmental disabilities. It remains to be determined what is the most appropriate treatment of other causes. The diagnosis and treatment of neonatal diabetes, therefore, represents a model for personalized medicine. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434356      PMCID: PMC2914172          DOI: 10.1016/j.tem.2010.03.004

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  104 in total

1.  Treatment of hyperglycemia in a 7-year-old child diagnosed with neonatal diabetes.

Authors:  Eba Hathout; John Mace; Graeme I Bell; Pål R Njølstad
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

2.  Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.

Authors:  A S Slingerland; R Nuboer; M Hadders-Algra; A T Hattersley; G J Bruining
Journal:  Diabetologia       Date:  2006-09-19       Impact factor: 10.122

3.  New ABCC8 mutations in relapsing neonatal diabetes and clinical features.

Authors:  Martine Vaxillaire; Aurélie Dechaume; Kanetee Busiah; Hélène Cavé; Sabrina Pereira; Raphael Scharfmann; Guiomar Perez de Nanclares; Luis Castano; Philippe Froguel; Michel Polak
Journal:  Diabetes       Date:  2007-03-27       Impact factor: 9.461

Review 4.  Function and distribution of the SUR isoforms and splice variants.

Authors:  Nian-Qing Shi; Bin Ye; Jonathan C Makielski
Journal:  J Mol Cell Cardiol       Date:  2005-02-05       Impact factor: 5.000

5.  Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism.

Authors:  Valérie Senée; Claude Chelala; Sabine Duchatelet; Daorong Feng; Hervé Blanc; Jack-Christophe Cossec; Céline Charon; Marc Nicolino; Pascal Boileau; Douglas R Cavener; Pierre Bougnères; Doris Taha; Cécile Julier
Journal:  Nat Genet       Date:  2006-05-21       Impact factor: 38.330

6.  KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.

Authors:  Anna L Gloyn; Catherine Diatloff-Zito; Emma L Edghill; Christine Bellanné-Chantelot; Sylvie Nivot; Régis Coutant; Sian Ellard; Andrew T Hattersley; Jean Jacques Robert
Journal:  Eur J Hum Genet       Date:  2006-05-03       Impact factor: 4.246

7.  Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus.

Authors:  Wei-Hsin Ting; Chi-Yu Huang; Fu-Sung Lo; Hung-Chang Lee; Chong-Ling Lin; Wen-Ling Guo; Yann-Jinn Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2009-07       Impact factor: 1.634

8.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

Authors:  Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Transient neonatal diabetes mellitus. Treatment with chlorpropamide.

Authors:  P Kuna; D P Addy
Journal:  Am J Dis Child       Date:  1979-01

10.  The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

Authors:  Joseph C Koster; Francesco Cadario; Cinzia Peruzzi; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

View more
  23 in total

1.  Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.

Authors:  Brian W Thurber; David Carmody; Elizabeth C Tadie; Ashley N Pastore; Jazzmyne T Dickens; Kristen E Wroblewski; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  Diabetologia       Date:  2015-04-17       Impact factor: 10.122

2.  Creation of the Web-based University of Chicago Monogenic Diabetes Registry: using technology to facilitate longitudinal study of rare subtypes of diabetes.

Authors:  Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

3.  Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.

Authors:  Farzaneh Abbasi; Sadaf Saba; Azadeh Ebrahim-Habibi; Forough A Sayahpour; Parvin Amiri; Bagher Larijani; Mahsa M Amoli
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

Review 4.  Current understanding of K ATP channels in neonatal diseases: focus on insulin secretion disorders.

Authors:  Yi Quan; Andrew Barszczyk; Zhong-ping Feng; Hong-shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2011-05-23       Impact factor: 6.150

5.  Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

Authors:  David Carmody; Charles D Bell; Jessica L Hwang; Jazzmyne T Dickens; Daniela I Sima; Dania L Felipe; Carrie A Zimmer; Ajuah O Davis; Kateryna Kotlyarevska; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

6.  The Krüppel-like zinc finger protein GLIS3 transactivates neurogenin 3 for proper fetal pancreatic islet differentiation in mice.

Authors:  Y Yang; B H-J Chang; V Yechoor; W Chen; L Li; M-J Tsai; L Chan
Journal:  Diabetologia       Date:  2011-07-23       Impact factor: 10.122

7.  Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2(C95S)).

Authors:  S Kautz; L van Bürck; M Schuster; E Wolf; R Wanke; N Herbach
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

Review 8.  Understanding childhood diabetes mellitus: new pathophysiological aspects.

Authors:  Juergen Grulich-Henn; Daniela Klose
Journal:  J Inherit Metab Dis       Date:  2017-12-15       Impact factor: 4.982

Review 9.  Diabetes mellitus due to the toxic misfolding of proinsulin variants.

Authors:  Michael A Weiss
Journal:  FEBS Lett       Date:  2013-05-10       Impact factor: 4.124

10.  Novel perspectives of super-high dose sulfonylurea and high-dose oral prednisolone in an infant with DEND syndrome due to V64M heterozygote KCNJ11 mutation.

Authors:  Galia Barash; Haim Bassan; Ayelet Livne; Lilach Benyamini; Eli Heyman; Pamela Bowman; Marianna Rachmiel
Journal:  Acta Diabetol       Date:  2021-07-16       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.